Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Cash from Operations (2023 - 2025)

Historic Cash from Operations for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $100.4 million.

  • Monte Rosa Therapeutics' Cash from Operations rose 57836.52% to $100.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.1 million, marking a year-over-year increase of 36031.21%. This contributed to the annual value of $42.0 million for FY2024, which is 19587.69% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Cash from Operations of $100.4 million as of Q3 2025, which was up 57836.52% from -$34.7 million recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Cash from Operations peaked at $128.9 million during Q4 2024, and registered a low of -$45.5 million during Q1 2025.
  • In the last 3 years, Monte Rosa Therapeutics' Cash from Operations had a median value of -$24.7 million in 2023 and averaged $1.7 million.
  • As far as peak fluctuations go, Monte Rosa Therapeutics' Cash from Operations plummeted by 6305.65% in 2024, and later soared by 57836.52% in 2025.
  • Monte Rosa Therapeutics' Cash from Operations (Quarter) stood at $29.6 million in 2023, then skyrocketed by 335.05% to $128.9 million in 2024, then dropped by 22.1% to $100.4 million in 2025.
  • Its last three reported values are $100.4 million in Q3 2025, -$34.7 million for Q2 2025, and -$45.5 million during Q1 2025.